On July 15, 2026, the U.S. Food and Drug Administration accepted for filing the New Drug Application for AXS-12 (reboxetine) to treat cataplexy in patients with narcolepsy. Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders.
